Zobrazeno 1 - 10
of 778
pro vyhledávání: ''
Autor:
Louise Bondeelle, Slim Fourati, Charles Soler, Anne-Laure Houist, Jean-Hugues Dalle, Sylvie Chevret, Maud Salmona, Tereza Coman, Franck Griscelli, Anne Bergeron, Jérôme LeGoff, Véronique Houdouin, Régis Peffault de Latour, Christine Robin, Frédéric Rivière
Publikováno v:
Bone Marrow Transplantation
Haematopoietic stem cell transplantation (HSCT) recipients are at risk for severe respiratory syncytial virus (RSV) infection. Two prognostic scores have been proposed to predict the risk of progression from upper respiratory tract infection (URTI) t
Publikováno v:
Bone Marrow Transplantation
Allogeneic hematopoietic stem cell transplantation (alloSCT) carries the promise of cure for many malignant and non-malignant diseases of the lympho-hematopoietic system. Although outcome has improved considerably since the pioneering Seattle achieve
Autor:
Roni Shouval, Angharad Pryce, Richard Szydlo, Avichai Shimoni, Jiri Pavlu, Mika Geva, Arnon Nagler, Noga Shem-Tov, Ivetta Danylesko, Joshua A Fein, Ronit Yerushalmi
Publikováno v:
Bone Marrow Transplantation. 56:2690-2696
Risk stratification is important for balancing potential risks and benefits of allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. We retrospectively studied 1119 patients undergoing allogenic-HSCT in a single ce
Autor:
Riad El Fakih, Mohsen Alzahrani, Abdulaziz Hamadah, Khalil Al-Farsi, Tusneem Elhassan, Mohammed F. Essa, Alfadil Haroon, Reem S. Almaghrabi, Khalid Al Anezi, Naif I. AlJohani, Panayotis Kaloyannidis, Ibraheem H. Motabi, Mouhab Ayas, Ashraf M. Suhebeh, Imran K Tailor, Ahmad Alsaeed, Ahmad Alhuraiji, Murtadha Al-Khabori, Moussab Damlaj, Mahmoud Aljurf, Bader Alahmari, Hani Al Hashmi, Syed Osman Ahmed, Sameer Alamoudi, Ibraheem Abosoudah, Feras Alfraih, Saud Alhayli
Publikováno v:
Bone Marrow Transplantation
Background: The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised a
Autor:
Katsuyoshi Koh, Yoshiyuki Kosaka, Maiko Noguchi, Yoshiko Hashii, Takako Miyamura, Tomoko Yokosuka, Daisuke Tomizawa, Takashi Taga, Tsukasa Hori, Maho Sato, Hirotoshi Sakaguchi, Yoshiko Atsuta, Masami Inoue, Nao Yoshida, Yasuhiro Okamoto, Masanobu Takeuchi, Keiko Okada, Hiroyuki Ishida
Publikováno v:
Bone Marrow Transplantation. 56:1859-1865
Children with acute myeloid leukemia (AML) commonly develop extramedullary disease (EMD), which comprises central nervous system (CNS) lesions and myeloid sarcoma (MS). In this retrospective analysis, we aimed to determine the effect of EMD on the ou
Autor:
He Huang, Qin Yu, Huijun Xu, Guoqing Wei, Mi Shao, Xinyi Teng, Xin Guo, Alex Hongsheng Chang, Yongxian Hu, Jiazhen Cui
Publikováno v:
Bone Marrow Transplantation. 56:1642-1650
Chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) has shown promising effects in the treatment of patients with refractory/relapsed multiple myeloma (R/R MM) patients. In this retrospective analysis of phase
Autor:
Ruth Pettengell, Ariane Boumendil, Joanna Romejko-Jarosinska, R Johnson, Peter Dreger, Stephen P. Robinson, Alejandro Martín, Eva Kimby, N. Schmitz, P Giri, Carsten Utoft Niemann, Anthony H. Goldstone, Isabelle Bence-Bruckler, Bernd Metzner, Silvia Montoto, Ruzena Uddin
Publikováno v:
Bone Marrow Transplantation. 56:1413-1421
We report the 12-year follow-up of the prospective randomized EBMT LYM1 trial to determine whether the benefit of brief duration rituximab maintenance (RM) on progression-free survival (PFS) in patients with relapsed follicular lymphoma (FL) receivin
Autor:
Shingo Yano, Satoshi Takahashi, Heiwa Kanamori, Maki Hagihara, Akira Yokota, Nobuyuki Aotsuka, Emiko Sakaida, Yoshihiro Hatta, Shinichiro Okamoto, Toru Sakura, Reiko Watanabe, Takehiko Mori, Makoto Onizuka, Yoshinobu Kanda, Shin ichiro Fujiwara, Moritaka Gotoh, Hideki Nakasone, Shinichi Kako, Shin Fujisawa, Nobuhiro Tsukada, Kensuke Usuki
Publikováno v:
Bone Marrow Transplantation. 56:1402-1412
For patients with Philadelphia chromosome (Ph)-positive leukemia, there is no consensus regarding how long tyrosine kinase inhibitors (TKI) should be given or whether TKI could be stopped if TKI is administrated after allogeneic hematopoietic cell tr
Autor:
Huan Chen, Xiao-Jun Huang, Wei Han, Yan Su, Feng-Rong Wang, Hai-Xia Fu, Xiao-Hui Zhang, Yu-Hong Chen, Yao Chen, Xiao Liu, Yun He, Lan-Ping Xu, Yuan-Yuan Zhang, Xiao-Lu Zhu, Kai-Yan Liu, Feng-Qi Liu, Gao-Chao Zhang, Qi Chen, Yu Wang, Jing-Zhi Wang, X. F. Sun, Yi-Fei Cheng, Xiao-Dong Mo
Publikováno v:
Bone Marrow Transplant
Gastrointestinal bleeding (GIB) accounts for a significant proportion of life-threatening bleeding cases occurring after allogeneic haematopoietic stem cell transplantation (allo-HSCT). However, data on GIB after haploidentical HSCT (haplo-HSCT) are
Autor:
Yoshihiro Inamoto, Tomonari Takemura, Masatomo Kuno, Takahiro Fukuda, Saiko Kurosawa, Kinuko Tajima, Takashi Tanaka, Akihisa Kawajiri, Sung-Won Kim, Ayumu Ito, Kazuki Sakatoku, Kyosuke Yamaguchi
Publikováno v:
Bone Marrow Transplantation. 56:1335-1340
To elucidate the incidence, causes, and risk factors associated with readmission due to transplant-related complications, we studied 213 consecutive patients who were discharged without progression of primary disease after their first allogeneic hema